CGRP Receptor Antagonists with Tertiary Amide End Groups
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for migraine and other CGRP-related disorders are limited in efficacy and specificity, as existing antagonists may have side effects and are not universally effective across all CGRP-mediated conditions.
Innovation Solution
Development of novel compounds that act as selective antagonists for CGRP receptors, specifically designed to target and inhibit CGRP-mediated pathways, thereby reducing vasodilation and neuronal sensitization associated with migraine and other conditions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing CGRP antagonists are used, then migraine treatment is achieved, but side effects occur and efficacy is limited
Solution Approach 1:
The patent modifies the chemical structure of CGRP antagonists by changing parameters such as introducing tertiary amide, sulfonamide, carbamate or urea end groups, and adjusting amino acid sequences. These structural parameter changes result in compounds with improved efficacy and reduced side effects compared to existing antagonists, directly resolving the contradiction between reliability and harmful factors.
2Reliability
If existing CGRP antagonists are used, then CGRP-mediated pathways are inhibited, but specificity is reduced
Solution Approach 1:
The patent introduces specific functional groups (tertiary amide, sulfonamide, carbamate, urea) at particular positions in the peptide sequence to create local structural features that enhance receptor binding specificity. This localized modification allows the antagonists to specifically target CGRP receptors while maintaining effectiveness across different CGRP-mediated conditions, resolving the contradiction between specificity and universal effectiveness.
3Reliability
If novel compounds are developed with improved structure, then efficacy and specificity are improved, but manufacturing complexity increases
Solution Approach 1:
The patent divides the CGRP antagonist molecule into distinct functional segments: a core peptide sequence and modular end groups (tertiary amide, sulfonamide, carbamate, or urea). This segmentation allows for systematic variation of functional groups while maintaining the core structure, simplifying the manufacturing process by reducing the need to synthesize entirely new molecules from scratch.
Data Source
AI summary
Compounds of formula I:(wherein variables A, m, n, J, Re, Rf, R4, Ea, Eb, Ec, RPG and Y are as described herein) which are antagonists of CGRP receptors and which are useful in the treatment or prevention of diseases in which the CGRP is involved, such as migraine; and pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.